Latest Period
Q4 2025
Security Snapshot
Editas Medicine, Inc. - Common Stock (EDIT) Institutional Ownership
CUSIP: 28106W103
13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026
Institutions Reporting
190
Shares (Excl. Options)
49,932,457
Price
$2.05
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- EDIT on Nasdaq
- Shares outstanding
- 82,773,190
- Price per share
- $2.47
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 49,932,457
- Total reported value
- $102,456,919
- % of total 13F portfolios
- 0%
- Share change
- +7,172,630
- Value change
- +$13,787,276
- Number of holders
- 190
- Price from insider filings
- $2.47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- EDIT - Editas Medicine, Inc. - Common Stock is tracked under CUSIP 28106W103.
- 190 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 190 to 51 between Q4 2025 and Q1 2026.
- Reported value moved from $102,456,919 to $7,052,575.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 190 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 28106W103?
CUSIP 28106W103 identifies EDIT - Editas Medicine, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28106W103:
Significant Owners of Editas Medicine, Inc. - Common Stock (EDIT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.9% | $10,527,922 | 6,539,082 | BlackRock, Inc. | 31 Mar 2025 |
As of 31 Dec 2025, 190 institutional investors reported holding 49,932,457 shares of Editas Medicine, Inc. - Common Stock (EDIT). This represents 60% of the company’s total 82,773,190 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Editas Medicine, Inc. - Common Stock (EDIT) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | 9,347,114 | +17% | 0% | $19,161,582 |
| VANGUARD GROUP INC | 9.9% | 8,208,068 | +18% | 0% | $16,826,539 |
| RENAISSANCE TECHNOLOGIES LLC | 3.7% | 3,039,778 | +138% | 0.01% | $6,231,545 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.8% | 2,284,740 | +12% | 0% | $4,684,759 |
| Nuveen, LLC | 2.4% | 1,976,900 | -5.5% | 0% | $4,052,645 |
| STATE STREET CORP | 2.4% | 1,974,931 | +2.6% | 0% | $4,048,609 |
| TWO SIGMA INVESTMENTS, LP | 2% | 1,632,584 | +3.1% | 0% | $3,346,797 |
| TWO SIGMA ADVISERS, LP | 1.5% | 1,224,100 | +1.6% | 0% | $2,509,405 |
| RAYMOND JAMES FINANCIAL INC | 1.4% | 1,184,670 | +623% | 0% | $2,428,573 |
| JANE STREET GROUP, LLC | 1.4% | 1,176,580 | +128% | 0% | $2,411,989 |
| D. E. Shaw & Co., Inc. | 1.3% | 1,109,590 | +855% | 0% | $2,274,659 |
| GOLDMAN SACHS GROUP INC | 1.1% | 881,960 | +92% | 0% | $1,808,018 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1% | 827,140 | +3.4% | 0.01% | $1,695,637 |
| CITADEL ADVISORS LLC | 0.99% | 820,993 | +127% | 0% | $1,683,035 |
| UBS Group AG | 0.98% | 809,342 | +92% | 0% | $1,659,151 |
| ACADIAN ASSET MANAGEMENT LLC | 0.97% | 799,847 | +124% | 0% | $1,635,000 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.96% | 794,671 | +1.9% | 0% | $1,629,076 |
| JPMORGAN CHASE & CO | 0.95% | 783,104 | -4.6% | 0% | $1,605,363 |
| Point72 Asset Management, L.P. | 0.89% | 733,483 | 0% | $1,503,640 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.85% | 704,662 | -12% | 0% | $1,444,557 |
| MORGAN STANLEY | 0.82% | 678,913 | -38% | 0% | $1,391,772 |
| NORTHERN TRUST CORP | 0.8% | 662,459 | -1.1% | 0% | $1,358,041 |
| AQR CAPITAL MANAGEMENT LLC | 0.78% | 644,197 | -6.3% | 0% | $1,320,604 |
| GSA CAPITAL PARTNERS LLP | 0.69% | 568,809 | 0.1% | $1,166,000 | |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.68% | 562,140 | -0.62% | 0.02% | $1,152,387 |
Institutional Holders of Editas Medicine, Inc. - Common Stock (EDIT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,847,762 | $7,052,575 | +$149,000 | $2.47 | 51 |
| 2025 Q4 | 49,932,457 | $102,456,919 | +$13,787,276 | $2.05 | 190 |
| 2025 Q3 | 43,042,863 | $149,310,576 | +$7,918,428 | $3.47 | 191 |
| 2025 Q2 | 41,335,195 | $90,959,890 | -$2,651,384 | $2.20 | 190 |
| 2025 Q1 | 44,017,732 | $51,056,496 | -$8,643,822 | $1.16 | 189 |
| 2024 Q4 | 51,050,083 | $64,829,211 | -$26,980,305 | $1.27 | 199 |
| 2024 Q3 | 55,026,910 | $187,727,875 | -$7,609,494 | $3.41 | 223 |
| 2024 Q2 | 56,388,612 | $263,332,828 | -$55,730,958 | $4.67 | 229 |
| 2024 Q1 | 67,934,083 | $503,995,838 | +$62,859,602 | $7.42 | 221 |
| 2023 Q4 | 58,810,431 | $595,736,469 | -$24,830,057 | $10.13 | 222 |
| 2023 Q3 | 61,671,930 | $481,001,719 | -$15,318,112 | $7.80 | 220 |
| 2023 Q2 | 62,806,728 | $516,820,804 | +$83,105,555 | $8.23 | 234 |
| 2023 Q1 | 52,966,709 | $383,993,662 | -$13,671,500 | $7.25 | 231 |
| 2022 Q4 | 54,069,648 | $479,580,650 | +$43,275,611 | $8.87 | 245 |
| 2022 Q3 | 48,268,099 | $590,813,665 | +$8,782,042 | $12.24 | 243 |
| 2022 Q2 | 47,470,750 | $561,353,937 | +$5,825,446 | $11.83 | 235 |
| 2022 Q1 | 45,377,308 | $862,213,005 | -$137,494,973 | $19.02 | 239 |
| 2021 Q4 | 50,935,353 | $1,354,989,098 | -$58,058,784 | $26.55 | 288 |
| 2021 Q3 | 51,686,909 | $2,124,275,170 | -$9,901,736 | $41.08 | 307 |
| 2021 Q2 | 52,115,846 | $2,960,972,143 | -$42,349,447 | $56.64 | 309 |
| 2021 Q1 | 53,112,966 | $2,230,651,006 | -$37,048,235 | $42.00 | 296 |
| 2020 Q4 | 52,925,101 | $3,710,809,621 | -$146,422,850 | $70.11 | 303 |
| 2020 Q3 | 55,153,663 | $1,547,459,830 | +$15,957,942 | $28.06 | 233 |
| 2020 Q2 | 54,180,331 | $1,601,145,803 | +$263,790,568 | $29.58 | 225 |
| 2020 Q1 | 45,615,983 | $904,572,484 | -$9,115,772 | $19.83 | 186 |
| 2019 Q4 | 45,765,436 | $1,355,110,145 | +$25,771,039 | $29.61 | 221 |
| 2019 Q3 | 44,998,047 | $1,024,181,318 | +$117,742,869 | $22.74 | 180 |
| 2019 Q2 | 39,755,008 | $983,423,600 | +$65,857,366 | $24.74 | 187 |
| 2019 Q1 | 37,451,919 | $915,659,367 | +$73,756,065 | $24.45 | 194 |
| 2018 Q4 | 34,476,789 | $784,057,800 | +$24,196,841 | $22.75 | 187 |
| 2018 Q3 | 33,225,759 | $1,057,110,921 | +$32,891,792 | $31.82 | 192 |
| 2018 Q2 | 32,137,091 | $1,150,684,888 | +$38,224,646 | $35.83 | 208 |
| 2018 Q1 | 31,152,906 | $1,032,691,989 | +$25,997,611 | $33.15 | 192 |
| 2017 Q4 | 30,385,119 | $934,032,943 | +$80,818,257 | $30.73 | 146 |
| 2017 Q3 | 27,385,418 | $657,479,359 | +$43,906,788 | $24.01 | 115 |
| 2017 Q2 | 25,837,623 | $433,614,752 | +$21,311,417 | $16.78 | 107 |
| 2017 Q1 | 27,537,538 | $614,414,843 | +$120,573,551 | $22.32 | 99 |
| 2016 Q4 | 23,494,260 | $381,310,290 | +$21,340,854 | $16.23 | 84 |
| 2016 Q3 | 22,215,862 | $299,468,288 | +$9,006,129 | $13.48 | 71 |
| 2016 Q2 | 17,634,311 | $429,193,163 | -$15,061,641 | $24.40 | 64 |
| 2016 Q1 | 18,151,358 | $625,254,000 | +$464,066,000 | $34.54 | 48 |